Business Wire·Oct 21, 2026, 4:22 PM ET

Arcus Biosciences Announces Commencement of Public Offering of Common Stock

Arcus Biosciences Inc. announced it commenced an underwritten public offering of its common stock.
All shares in the offering are being sold by Arcus Biosciences.
The company intends to grant underwriters a 30-day option to purchase up to 15% additional shares.
Jefferies, Leerink Partners & TD Cowen are acting as joint book-running managers.
The offering is subject to market conditions, with no assurance regarding completion, size, or terms.
A shelf registration statement filed with the SEC on February 25, 2026, automatically became effective.
Preliminary prospectus supplements & accompanying prospectuses are available via the SEC's EDGAR website or by contacting the underwriters.
The press release includes forward-looking statements regarding the offering's timing & completion subject to various risks.
Investor inquiries can be directed to Pia Eaves, VP of Investor Relations & Strategy.
Media inquiries can be directed to Holli Kolkey or Maryam Bassiri of the Corporate Affairs team.